PK/PD-integrated Bayesian platform design for phase II dose regimen optimization
A Bayesian phase II adaptive platform design for regimen optimization that integrates pharmacokinetic/pharmacodynamic (PK/PD) modelling into toxicity, efficacy, regimen selection and adaptation decisions is developed.